When CareDx reports a quarter, the conversation defaults to testing volume. Q3 2026 delivered 75,900 tests, up 51% year over year. Q2 delivered 58,000, up 17%. The numbers are real and they matter. But volume alone flatters the simpler read. The more durable signal is what CareDx collects per test, and how a newly bolted-on oncology business is widening the revenue base in ways the headline figures do not capture.
Start with the core transplant franchise. Excluding specialty oncology, transplant revenue per test hit $1,514 in Q3, growing 15% year over year. That is not just a mix shift toward higher-acuity cases. Revenue growth has reflected favorable reimbursement dynamics alongside increases in testing activity across both surveillance and for-cause settings. Payer collections are improving, and the company has been systematically reinstituting surveillance protocols at centers that previously used molecular testing only reactively. There are centers in the United States that do not use molecular testing at all, and others that use it only in the for-cause setting with no surveillance program. Each converted center represents a recurring revenue stream, not a one-time event.
The second engine is NavDx, acquired when CareDx closed the Naveris deal on July 1 for approximately $203 million in total consideration. NavDx is a blood-based test that detects and monitors viral-mediated cancers, including HPV-associated head and neck and anal cancers, and is covered by Medicare for HPV-driven cancer surveillance. In 2025, Naveris generated approximately $35 million in revenue, more than doubling year over year. In its first full quarter inside CareDx, specialty oncology generated $12.5 million in quarterly revenues, representing 37% comparable year-over-year growth. Revenue per specialty oncology test came in at $823, running 6% above the company’s own forecast of $775.
Put both engines together and the guidance revisions tell the story. CareDx entered 2026 guiding to $420 million to $444 million in revenue. After three quarters, the company now expects full-year revenue of $520 million to $530 million. That is roughly a 20% revenue guide-raise inside a single calendar year.
Guidance upgrade cycles in medical technology tend to reward companies that are expanding their installed base rather than simply raising prices. Intuitive Surgical’s deliberate trade of near-term revenue per procedure for a larger long-run installed base shows how platform medtech companies sustain compounding growth.
The balance sheet carries $250 million in cash and no debt as of September 30. Management has the flexibility to invest in the 2027 pipeline, which includes additional molecular diagnostic launches across transplant and oncology, without diluting shareholders to fund it.
Management’s longer-range expectation is 15% annual transplant business growth and 30% to 40% NavDx growth through 2027. Those targets look achievable given current trajectory. Traders watching CDNA need to track two things: whether Q4 transplant revenue per test holds above $1,500 and whether NavDx volume exits the year above 16,000 tests. If both happen, the guidance upgrade cycle has another leg.
